Literature DB >> 16984867

Cryptococcosis.

Methee Chayakulkeeree1, John R Perfect.   

Abstract

In the past 2 decades, Cryptococcus has emerged in its clinical significance and as a model yeast for understanding molecular pathogenesis. C neoformans and C gattii are currently considered major primary and secondary pathogens in a wide array of hosts that are known to be immunocompromised or apparently immunocompetent. A recent outbreak of C gattii infections further underscores the clinical importance of the yeast through its epidemiology and pathogenicity features. With an enlarging immunosuppressed population caused by HIV infection, solid organ transplantation, and clinical use of potent immunosuppressives, such as cancer chemotherapy, monoclonal antibodies, and corticosteroids, this fungus has become a well-established infectious complication of modern medicine. This article examines current issues in cryptococcal infections, including new classification, epidemiology, pathogenesis, and specific clinical aspects.

Entities:  

Mesh:

Year:  2006        PMID: 16984867     DOI: 10.1016/j.idc.2006.07.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  131 in total

1.  Pseudomonas aeruginosa inhibits the growth of Cryptococcus species.

Authors:  Antonella Rella; Mo Wei Yang; Jordon Gruber; Maria Teresa Montagna; Chiara Luberto; Yong-Mei Zhang; Maurizio Del Poeta
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

2.  Challenges in dealing with a cirrhotic patient.

Authors:  Diana Spinelli; Sarah Damanti; Francesca Minonzio; Cinzia Hu; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2012-03-15       Impact factor: 3.397

3.  Isolation of Cryptococcus gattii from a Castanopsis argyrophylla tree hollow (Mai-Kaw), Chiang Mai, Thailand.

Authors:  Kantarawee Khayhan; Ferry Hagen; Treepradab Norkaew; Tanpalang Puengchan; Teun Boekhout; Pojana Sriburee
Journal:  Mycopathologia       Date:  2017-03-06       Impact factor: 2.574

Review 4.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

Review 5.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

6.  Headache, personality changes and fine motor disturbances.

Authors:  Johann Braun
Journal:  BMJ Case Rep       Date:  2009-02-26

7.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.

Authors:  Admasu Tenna Mamuye; Ethan Bornstein; Obsie Temesgen; Henry M Blumberg; Russell R Kempker
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

9.  Disseminated cryptococcosis in HIV-uninfected patients.

Authors:  Y-M Chuang; Y-C Ho; H-T Chang; C-J Yu; P-C Yang; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04       Impact factor: 3.267

10.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.